Hers Women's Health, MD-Led Platform

Hers is the women's health brand of Hims & Hers Health, a publicly traded telehealth company founded in 2017 and headquartered in San Francisco. Hims launched first as a men's telehealth platform for hair loss and erectile dysfunction, and introduced Hers in 2018 as a parallel brand addressing women's dermatology, birth control, and hair care. Over the following years, Hers expanded significantly into mental health, weight management, and perimenopause, becoming one of the broadest-scope direct-to-consumer women's health platforms in the United States. Hers operates on an asynchronous model: patients complete an online intake questionnaire, a licensed provider reviews the submission, and — if clinically appropriate — a prescription is issued and shipped directly to the patient's home. This model prioritizes speed and convenience over the depth of a traditional clinical relationship. Hers does not require scheduled appointments for most conditions, and most patients receive a prescription decision and initial shipment within a few business days. The tradeoff is a shallower clinical evaluation than a synchronous video visit allows, which is a meaningful limitation for conditions that benefit from detailed history-taking and physical exam context. The platform is notable for its breadth. In the same app, a patient can address anxiety (SSRI or buspirone if appropriate), hair thinning (minoxidil or spironolactone), perimenopause symptoms (low-dose estrogen or progesterone), weight loss (GLP-1 agonists or oral medications), and birth control — a combination of needs that would normally require visits to multiple specialists. For the growing segment of women juggling multiple overlapping health concerns with limited time for appointments, this one-stop convenience is a genuine differentiator. Hers does not accept insurance, which is the platform's primary structural limitation. All payments are out-of-pocket, and HSA/FSA coverage is also not accepted as of 2025. This makes Hers most economical for patients whose concerns are not covered by insurance or who lack coverage for telehealth specialty visits, but it is a less attractive option for patients with comprehensive commercial insurance who could access specialist menopause or mental health care at a $20–$50 copay through platforms like Midi or Stella. In November 2025, Hims & Hers launched a Labs service offering 120+ biomarker testing with personalized health plan outputs, extending the platform's data-driven approach to preventive health monitoring. The company also expanded to the UK and Canada in 2025, reflecting its ambition to replicate the D2C telehealth model in markets with similar healthcare access gaps. birth control, and hair care. Over the following years, Hers expanded significantly into mental health, weight management, and perimenopause, becoming one of the broadest-scope direct-to-consumer women's health platforms in the United States. Hers operates on an asynchronous model: patients complete an online intake questionnaire, a licensed provider reviews the submission, and — if clinically appropriate — a prescription is issued and shipped directly to the patient's home. This model prioritizes speed and convenience over the depth of a traditional clinical relationship. Hers does not require scheduled appointments for most conditions, and most patients receive a prescription decision and initial shipment within a few business days. The tradeoff is a shallower clinical evaluation than a synchronous video visit allows, which is a meaningful limitation for conditions that benefit from detailed history-taking and physical exam context. The platform is notable for its breadth. In the same app, a patient can address anxiety (SSRI or buspirone if appropriate), hair thinning (minoxidil or spironolactone), perimenopause symptoms (low-dose estrogen or progesterone), weight loss (GLP-1 agonists or oral medications), and birth control — a combination of needs that would normally require visits to multiple specialists. For the growing segment of women juggling multiple overlapping health concerns with limited time for appointments, this one-stop convenience is a genuine differentiator. Hers does not accept insurance, which is the platform's primary structural limitation. All payments are out-of-pocket, and HSA/FSA coverage is also not accepted as of 2025. This makes Hers most economical for patients whose concerns are not covered by insurance or who lack coverage for telehealth specialty visits, but it is a less attractive option for patients with comprehensive commercial insurance who could access specialist menopause or mental health care at a $20–$50 copay through platforms like Midi or Stella. In November 2025, Hims & Hers launched a Labs service offering 120+ biomarker testing with personalized health plan outputs, extending the platform's data-driven approach to preventive health monitoring. The company also expanded to the UK and Canada in 2025, reflecting its ambition to replicate the D2C telehealth model in markets with similar healthcare access gaps.